Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 200 of 2065 results for work

  1. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  2. HTA Lab projects

    Home What NICE does Our research work HTA Lab...

  3. Pancreatic cancer (QS177)

    This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.

  4. Getting involved as a voluntary and community sector organisation

    Getting involved with NICE as a voluntary and community sector organisation

  5. Involving you in the development of our guidance

    Involving you in the development of NICE guidance.

  6. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.

  7. Hepatitis B (QS65)

    This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.

  8. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  9. Positive workplaces for social workers

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...

  10. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  11. Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)

    NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.

    Sections for TA965

  12. Physical activity for children and young people (PH17)

    This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.

  13. Sarcoma (QS78)

    This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.

  14. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

  15. Principal social workers - children

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers...

  16. Suicide prevention (QS189)

    This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.

  17. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  22 April 2026

  18. Join our people and communities network

    Join NICE's people and communities network

  19. Domestic violence and abuse (QS116)

    This quality standard covers services for domestic violence and abuse in adults and young people (aged 16 and over). It includes identifying and supporting people experiencing domestic violence or abuse, as well as support for those who carry it out. It also covers children and young people (under 16) who are affected by domestic violence or abuse that is not carried out against them. It describes high-quality care in priority areas for improvement.

  20. Flu vaccination: increasing uptake (QS190)

    This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.

  21. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  22. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  23. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

  24. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

  25. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

  26. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

  27. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)

    Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.

  28. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

  29. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

  30. Acne

    Awaiting development Reference number: GID-QS10036 Expected publication date: TBC

  31. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

  32. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

  33. Diverticular disease

    Awaiting development Reference number: GID-QS10086 Expected publication date: TBC

  34. Thyroid disease

    Awaiting development Reference number: GID-QS10088 Expected publication date: TBC

  35. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

  36. Pain management (young people and adults)

    Awaiting development Reference number: GID-QS10093 Expected publication date: TBC

  37. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

  38. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

  39. Heart valve disease in adults

    Awaiting development Reference number: GID-QS10101 Expected publication date: TBC

  40. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

  41. Vulnerable populations: strategies for tackling inequalities

    Awaiting development Reference number: GID-QS10124 Expected publication date: TBC

  42. Pelvic floor dysfunction

    Awaiting development Reference number: GID-QS10129 Expected publication date: TBC

  43. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

  44. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

  45. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

  46. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development Reference number: GID-QS10146 Expected publication date: TBC

  47. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

  48. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

  49. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

  50. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC